MYCOPHENOLATE MOFETIL

Mycophenolate mofetil is the morpholinoethylester prodrug of mycopheno lic acid, an agent that inhibits the proliferation of B and T lymphocy tes through noncompetitive, reversible inhibition of inosine monophosp hate dehydrogenase, a key enzyme in the de novo synthetic pathway of g uanine nucleotides. Currently, mycophenolate mofetil is approved for t he prevention of acute renal allograft rejection when given in combina tion with cyclosporine and steroids. Several studies also demonstrated that the agent is effective in the treatment of refractory rejection in renal, heart, and liver transplant recipients, and may have efficac y in the treatment of chronic rejection as well.